Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celebrex, Bextra Given Breathing Room In Latest FDA Advisory

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency suggests any regulatory action on COX-2s or non-selective NSAIDs will wait until after a February advisory committee meeting. A public health advisory urges physicians to consider the “emerging” information on cardiovascular risk when prescribing COX-2s. FDA also orders a review of all prevention studies using Pfizer’s Celebrex and Bextra.

You may also be interested in...



COX-2 Inhibitor Meeting Expands To Three Days; GI/Cardiac Safety On Agenda

FDA advisory committees will consider overall benefit-risk of COX-2s and related products, both gastrointestinal safety and cardiovascular effects. The meeting will be held Feb. 16-18.

COX-2 Inhibitor Meeting Expands To Three Days; GI/Cardiac Safety On Agenda

FDA advisory committees will consider overall benefit-risk of COX-2s and related products, both gastrointestinal safety and cardiovascular effects. The meeting will be held Feb. 16-18.

Heart Concerns Shift To Aleve Following Alzheimer’s Trial

Preliminary data suggest long-term naproxen use caused a 50% increase in cardiovascular adverse events compared to placebo in a prematurely halted trial, which also included Pfizer's COX-2 inhibitor Celebrex (celecoxib)

Related Content

Topics

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel